Mount Sinai Names Samir Parekh, MD, as Director of the Center of Excellence for Multiple Myeloma
Samir Parekh, MD, a distinguished hematologist and researcher, has been named Director of the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. This appointment comes as Mount Sinai continues to expand its leadership in the field of multiple myeloma research, treatment, and patient care.
“Being named Director of the Center of Excellence for Multiple Myeloma is truly an honor,” said Dr. Parekh. “Mount Sinai has a world-leading program, and I am committed to furthering our mission of advancing research, improving patient outcomes, and ultimately finding a cure for multiple myeloma. We are witnessing a transformation in myeloma care, with patients now living for decades rather than just a few years. It is an exciting time to be in this field.”
Dr. Parekh, the Mount Sinai Professor in Cancer Biology, has dedicated his career to advancing the understanding and treatment of blood cancers. Coming from a family of hematologists in Mumbai, India, he developed his passion for hematologic research and patient care at an early age. His work integrates clinical practice with laboratory research, focusing on genomics and immunology to develop personalized treatment strategies for multiple myeloma patients.
"I am delighted to introduce Dr. Parekh as the director of our Multiple Myeloma Program. His expertise in translational research and patient care will be invaluable as we work together to advance innovative treatments and improve outcomes for patients,” said Sundar Jagannath, MD, the Center’s Founding Director, who will now step into the role of Network Director. “By combining our strengths, we will continue to push the boundaries of multiple myeloma research and provide the highest level of care to those we serve."
The Center of Excellence for Multiple Myeloma at Mount Sinai is one of the largest programs of its kind in the country, with a team of 10 physicians and 150 related staff who contribute to the Center’s clinical and research missions. The Center conducts cutting-edge clinical trials and has been instrumental in developing multiple Food and Drug Administration-approved treatments. With four locations and approximately 600 new patient referrals annually, the center serves a diverse patient population from New York City and the tristate area.
“Our focus remains on delivering outstanding patient care, fostering groundbreaking research, and ensuring equitable access to the latest therapies,” Dr. Parekh added. “Through strategic collaborations, including partnerships with industry and global myeloma experts, we aim to further refine personalized medicine approaches and develop novel treatment modalities.”
Mount Sinai’s commitment to advancing myeloma care is reflected in its robust research initiatives in genomics, biobanking, and immunology. As Mount Sinai continues to expand its reach, new initiatives include the establishment of a multiple myeloma program in Long Island and a collaboration with Valley Hospital in New Jersey to introduce CAR-T therapy to the region. These efforts are part of a broader vision to make advanced myeloma care more accessible to patients across the Northeast.
For more information about the Center of Excellence for Multiple Myeloma at Mount Sinai, please visit https://www.mountsinai.org/care/cancer/services/multiple-myeloma.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight- member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population.
The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 500 postdoctoral research fellows.
Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.
-------------------------------------------------------
* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, employing 48,000 people across its hospitals and more than 400 outpatient practices, as well as more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race
Sep 29, 2023 View All Press Releases
Researchers Find Treatment Options for Patients Whose Blood Cancer Relapses After CAR-T
Nov 04, 2022 View All Press Releases
Unprecedented Therapy Found Effective for Blood Cancer Patients With No Treatment Options
Aug 22, 2019 View All Press Releases